title: Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
abstract: Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously.
authors.affiliation: Department of Medical Oncology, Gazi University, Ankara, Turkey.
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Ozlem
authors.initials: O
authors.lastname: Erdem
authors.forename: Banu
authors.initials: B
authors.lastname: Ozturk
authors.forename: Isilay
authors.initials: I
authors.lastname: Bilge Yilmaz
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001706:Biopsy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000473:pathology; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects; D012393:Rosacea / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012880:Skin Pigmentation / Q000187:drug effects; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001549:Benzamides; D006633:Histamine Antagonists; D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib